A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

184

Participants

Timeline

Start Date

May 29, 2014

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions

MelanomaSolid Tumors

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Dabrafenib

oral capsule

DRUG

Trametinib

oral tablet

DRUG

Placebo

IV infusion